Silverarc Capital Management, LLC Eliem Therapeutics, Inc. Transaction History

Silverarc Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$2.48 - $3.15 $924,987 - $1.17 Million	-372,979 Reduced 75.49%	121,110 $318,000
Q2 2023 Aug 14, 2023	BUY	$2.34 - $3.72 $19,033 - $30,258	8,134 Added 1.67%	494,089 $1.38 Million
Q1 2023 May 15, 2023	BUY	$2.3 - $4.64 $176,531 - $356,133	76,753 Added 18.76%	485,955 $1.41 Million
Q4 2022 Feb 14, 2023	BUY	$2.48 - $3.69 $17,642 - $26,250	7,114 Added 1.77%	409,202 $1.5 Million
Q3 2022 Oct 28, 2022	SELL	$2.72 - $3.97 $845,705 - $1.23 Million	-310,921 Reduced 43.61%	402,088 $1.3 Million
Q2 2022 Jul 25, 2022	BUY	$2.77 - $8.4 $1.73 Million - $5.25 Million	624,730 Added 707.68%	713,009 $2.15 Million
Q1 2022 May 13, 2022	BUY	$8.01 - $13.15 $707,114 - $1.16 Million	88,279 New	88,279 $741,000

53.1M

Ticker ELYM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,567,700
Market Cap $109M
Description
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.